Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.72 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 4/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20983747 | 0.84 | ABHD6 (1.00) | ABHD6 | |
| SCHEMBL13336894 | 0.83 | MAPK1 (0.59) | ABHD6PIK3CAMTORNAMPTLMNA | |
| SCHEMBL11929929 | 0.80 | ABHD6 (0.70) | ABHD6PIK3CAMTOR | |
| SCHEMBL31336003 | 0.80 | ABHD6 (0.47) | ABHD6PIK3CAMTORCD274NAMPT | |
| SCHEMBL30368214 | 0.79 | PIK3CA (0.49) | ABHD6PIK3CAMTORNAMPTHDAC1 | |
| SCHEMBL25669120 | 0.79 | PIK3CA (0.49) | ABHD6PIK3CAMTORNAMPTHDAC1 | |
| SCHEMBL11929932 | 0.79 | ABHD6 (0.63) | ABHD6LMNA | |
| SCHEMBL3328948 | 0.78 | MTOR (0.55) | ABHD6PIK3CAMTORNAMPTHDAC1 | |
| SCHEMBL12177841 | 0.76 | HDAC1 (0.57) | PIK3CAMTORNAMPTHDAC1ESR2 | |
| SCHEMBL2809581 | 0.75 | ABHD6 (0.67) | ABHD6PIK3CAMTORNAMPTHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358736-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | Intermune, Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2010045266-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010045266-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | SARS1, VIP, MAVS | ABHD6 2815/4885PIK3CA 3569/4885MTOR 4015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.